|
業務類別
|
Biotechnology |
|
業務概覽
|
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a singleoperating segment, developing and commercializing therapeutics. |
| 公司地址
| 18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011 |
| 電話號碼
| +1 425 620-8501 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.leonabio.com |
| 員工數量
| 19 |
| Mr. Mark Worthington |
General Counsel, Chief Compliance Officer and Corporate Secretary |
美元 450.00K |
31/03/2026 |
| Dr. Kevin Church, PhD |
Chief Scientific Officer |
美元 450.00K |
31/03/2026 |
| Mr. Robert Renninger |
Chief Financial Officer and Principal Accounting Officer |
-- |
31/03/2026 |
| Dr. Mark J. Litton, PhD |
Director, President and Chief Executive Officer |
美元 625.00K |
31/03/2026 |
| Dr. Javier San Martin, M.D. |
Chief Medical Officer |
-- |
31/03/2026 |
|
|
| Mr. Grant E. Pickering |
Independent Director |
31/03/2026 |
| Mr. James A. Johnson |
Independent Director |
31/03/2026 |
| Ms. Barbara Kosacz, J.D. |
Independent Director |
31/03/2026 |
| Mr. Joseph Edelman |
Independent Director |
31/03/2026 |
| Ms. Kelly A. Romano |
Chairwoman of the Board |
31/03/2026 |
| Dr. Michael A. Panzara, M.D. |
Independent Director |
31/03/2026 |
| Dr. Mark J. Litton, PhD |
Director, President and Chief Executive Officer |
31/03/2026 |
| Mr. John M. Fluke, Jr |
Independent Director |
31/03/2026 |
|
|
|
|
